← Back to Search

Genetic Therapy

FCX-013 for Scleroderma

Phase 1 & 2
Waitlist Available
Research Sponsored by Castle Creek Biosciences, LLC.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4
Awards & highlights

Study Summary

This study is evaluating whether a combination of two therapies may help resolve fibrotic lesions in patients with localized scleroderma.

Eligible Conditions
  • Scleroderma
  • Localized Scleroderma
  • Morphea

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study initiation through study completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and study initiation through study completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluate the Safety of FCX-013 Plus Veledimex
Secondary outcome measures
Evaluate the Antifibrotic Effects of FCX-013 Plus Veledimex

Trial Design

1Treatment groups
Experimental Treatment
Group I: FCX-013 + veledimexExperimental Treatment2 Interventions
Following the injection of FCX-013, subjects will initiate a 14-day course of veledimex to be taken orally daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
veledimex
2015
Completed Phase 1
~100

Find a Location

Who is running the clinical trial?

Castle Creek Biosciences, LLC.Lead Sponsor
10 Previous Clinical Trials
644 Total Patients Enrolled
Mary C Spellman, MDStudy DirectorCastle Creek Biosciences, LLC.
Clinical Trial DirectorStudy DirectorCastle Creek Biosciences, LLC.
3 Previous Clinical Trials
94 Total Patients Enrolled
~0 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top